Graziano Seghezzi has been promoted to managing partner at Sofinnova Partners having first joined the Paris-based venture capital company in 2001. Mr Seghezzi has focused on company creation and was the seed investor in Omthera Pharmaceuticals Inc, which was bought by AstraZeneca Plc in 2013, and Glycovaxyn AG, bought by GlaxoSmithKline Plc in 2015. He also co-founded BiovelocITA, Italy’s first biotech accelerator. Mr Seghezzi left Sofinnova in 2003 to work for Index Ventures, returning in 2006.
A scientist by training, Mr Seghezzi spent five years in academic research at New York University School of Medicine focusing on oncology and cardiovascular diseases. He holds a degree in genetics and microbiology from the University of Pavia in Italy and an MBA from RSM-Erasmus University in the Netherlands.
Sofinnova announced the appointment on 22 May 2017.
Copyright 2017 Evernow Publishing Ltd